BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30236129)

  • 21. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NADPH oxidase gp91
    Kang IS; Kim C
    Sci Rep; 2016 Nov; 6():38014. PubMed ID: 27897222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased SH3BP2 inhibits osteoclast differentiation and function.
    Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
    J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.
    GuezGuez A; Prod'homme V; Mouska X; Baudot A; Blin-Wakkach C; Rottapel R; Deckert M
    J Biol Chem; 2010 Jul; 285(27):20952-63. PubMed ID: 20439986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-124 regulates osteoclast differentiation.
    Lee Y; Kim HJ; Park CK; Kim YG; Lee HJ; Kim JY; Kim HH
    Bone; 2013 Oct; 56(2):383-9. PubMed ID: 23867221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
    Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
    Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
    Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
    Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.
    Wu PF; Tang JY; Li KH
    Tumour Biol; 2015 Feb; 36(2):495-501. PubMed ID: 25618600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
    Yang L; Hai Y; Zhou JL
    Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation.
    Park K; Ju WC; Yeo JH; Kim JY; Seo HS; Uchida Y; Cho Y
    Int J Mol Med; 2014 Jan; 33(1):178-84. PubMed ID: 24248634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival.
    Fujiwara T; Zhou J; Ye S; Zhao H
    Cell Death Dis; 2016 Jul; 7(7):e2300. PubMed ID: 27441652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of SH3BP2 in the pathophysiology of cherubism.
    Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
    Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of Homeostasis in Pre-osteoclasts Induced by Aggregatibacter actinomycetemcomitans CDT.
    Kawamoto D; Ando-Suguimoto ES; Bueno-Silva B; DiRienzo JM; Mayer MP
    Front Cell Infect Microbiol; 2016; 6():33. PubMed ID: 27064424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.
    Warren JT; Zou W; Decker CE; Rohatgi N; Nelson CA; Fremont DH; Teitelbaum SL
    J Cell Biochem; 2015 Nov; 116(11):2476-83. PubMed ID: 25864714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
    Lietman SA; Yin L; Levine MA
    J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ionizing Radiation Stimulates Expression of Pro-Osteoclastogenic Genes in Marrow and Skeletal Tissue.
    Alwood JS; Shahnazari M; Chicana B; Schreurs AS; Kumar A; Bartolini A; Shirazi-Fard Y; Globus RK
    J Interferon Cytokine Res; 2015 Jun; 35(6):480-7. PubMed ID: 25734366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression.
    Zhao Z; Hou X; Yin X; Li Y; Duan R; Boyce BF; Yao Z
    PLoS One; 2015; 10(8):e0135728. PubMed ID: 26287732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.